This Phase I trial is evaluating how safe and tolerable a targeted therapy (cevostamab) is in people with relapsed or refractory multiple myelomoaAn Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Patients With Relapsed or Refractory Multiple Myeloma

Summary

This trial has one experimental arm with two stages. In Arm A1S (Single-Agent Safety Run-In), participants will be administered cevostamab in 28-day cycles on a modified weekly schedule, up to a total of 13 cycles. Upon completion of Arm A1S, Arm A1E (Single-Agent Expansion) may be opened. Participants will be treated with single-agent cevostamab administered in 28-day cycles on a modified weekly schedule. Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.